Araris Biotech

ararisbiotech.com
startup-icon Start-up

Araris Biotech AG

7 Otto-Stern-Weg
8049 Zürich
Switzerland
ararisbiotech.com
Profile Products News

About Araris Biotech

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Read more about Araris Biotech

Advertisement

Chemically Defined Cell Culture Media for Viral Vector and Gene Therapy Applications
Chemically Defined Cell Culture Media for Viral Vector and Gene Therapy Applications
High-Performance Sterilizing-Grade Filtration for Solvents and Oily Formulations
High-Performance Sterilizing-Grade Filtration for Solvents and Oily Formulations
Continuous Low‑pH Virus Inactivation for Integrated Bioprocessing
Continuous Low‑pH Virus Inactivation for Integrated Bioprocessing

Product portfolio of Araris Biotech

Product portfolio

Show all

Advertisement

Maximum binding capacity in ion exchange chromatography
Maximum binding capacity in ion exchange chromatography
Digital membrane chromatography opens up new horizons in protein analysis
Digital membrane chromatography opens up new horizons in protein analysis
High‑Performance Tangential Flow Filtration Solutions for Biopharmaceutical Processing
High‑Performance Tangential Flow Filtration Solutions for Biopharmaceutical Processing

News about Araris Biotech

Araris Biotech

15-Jul-2025 | business & finance

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies

Read news
Araris Biotech

02-Jun-2025 | business & finance

Strüngmann Award Committee Announces Finalists Recognizing Outstanding Life Science Entrepreneurs in the DACH Region

The award celebrates the next generation of leaders advancing a great idea into reality

Read news
Araris Biotech

15-Jan-2025 | business & finance

Araris Biotech announces research collaboration and option to license agreement with Chugai Pharmaceutical Co.

Araris to receive an upfront fee and milestone payments potentially totalling USD 780 million plus royalties on net product sales

Read news
Araris Biotech

10-Oct-2022 | business & finance

Araris Biotech Closes $24 Million Financing Round

"Araris continues to make waves in the industry with its pioneering linker technology, enabling fast and precise production of ADCs"

Read news
Show more news about Araris Biotech

Advertisement

Automated Filter Integrity Testing With Advanced Quality Risk Management for GMP Compliance
Automated Filter Integrity Testing With Advanced Quality Risk Management for GMP Compliance
3D Raman microscopes with unequalled speed, sensitivity and resolution
3D Raman microscopes with unequalled speed, sensitivity and resolution
Advanced CHO Cell Line Development Technology for In-House Implementation
Advanced CHO Cell Line Development Technology for In-House Implementation

Here you will find Araris Biotech AG

Last viewed contents

Immortal cells for tailor-made active substances

Immortal cells for tailor-made active substances

Go to page